Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells 8,902 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 8,902 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $201,719.32. Following the completion of the sale, the chief marketing officer now directly owns 135,956 shares of the company’s stock, valued at approximately $3,080,762.96. This trade represents a 6.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Todd Berard also recently made the following trade(s):

• On Tuesday, March 11th, Todd Berard sold 1,577 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $39,425.00.
• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total value of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total transaction of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $9,267.86.

BioLife Solutions Stock Down 5.6 %

NASDAQ BLFS opened at $22.44 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The stock’s 50 day moving average is $26.00 and its 200 day moving average is $25.51. The stock has a market cap of $1.05 billion, a PE ratio of -21.17 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the prior year, the business earned ($0.21) earnings per share. Research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Monday. KeyCorp lifted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Northland Securities upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. HC Wainwright lifted their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Finally, Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BLFS. Intech Investment Management LLC bought a new position in BioLife Solutions during the third quarter valued at approximately $255,000. Charles Schwab Investment Management Inc. boosted its position in shares of BioLife Solutions by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 319,959 shares of the medical equipment provider’s stock valued at $8,012,000 after acquiring an additional 9,750 shares during the last quarter. Cerity Partners LLC boosted its position in shares of BioLife Solutions by 6.6% during the 3rd quarter. Cerity Partners LLC now owns 44,914 shares of the medical equipment provider’s stock valued at $1,125,000 after acquiring an additional 2,776 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of BioLife Solutions by 40.8% in the third quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after purchasing an additional 5,638 shares in the last quarter. Finally, FMR LLC increased its position in BioLife Solutions by 470.6% in the third quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 10,983 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.